Project Grant R01CA294133
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$522K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $546,349 to The University of Texas Southwestern Medical Center to investigate a novel signaling pathway by which the von Hippel-Lindau (VHL) tumor suppressor regulates gene expression through mRNA methylation (m6A) in clear cell renal cell carcinoma (CCRCC). The research aims to characterize the molecular mechanism by which VHL interacts with the m6A...
This National Cancer Institute (NCI) Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" program aims to develop a prognostic assay to predict metastatic progression in clear cell renal cell carcinoma (cCRCC). The $927,997 award to Lagrange Scientific LLC, a small disadvantaged business, supports the expansion of a prototype metabolite-based biomarker panel that demonstrated 100% specificity and 83% sensitivity in pilot studies for identifying cCRCC patients at...
This $544,475 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel in vitro cancer metastasis model system using decellularized organ tissues, or "biomatrices." The primary objectives are to:
Generate a comprehensive panel of biomatrices representing common sites of cancer metastasis (e.g. liver, lung) to recapitulate organ-specific tumor biology and treatment response.
Demonstrate the...
This $396,061 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the potential therapeutic efficacy of newly synthesized boron-based inhibitors of the hypoxia-inducible factor (HIF) pathway as a treatment strategy for renal cell carcinoma (RCC).
The project has two specific aims: 1) determine the structure-activity relationship of honokiol analogs in inhibiting the HIF pathway, and 2) evaluate the efficacy of selected...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $483,395 to The Institute For Cancer Research to develop a novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cell carcinoma (RCC). The key objectives are to: (1) engineer a tumor-specific anti-CD70-IL-21 fusion antibody with superior pharmacokinetic/pharmacodynamic properties compared to systemic IL-21 administration; (2)...
This federal Project Grant award of $368,288 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to identify small molecule inhibitors that can disrupt the protein-protein interactions of the TFE3 chimeric proteins in translocation renal cell carcinoma (TRCC). The primary products or services to be delivered under this 5-year grant include:
Optimizing lead compounds and screening for novel small molecules that can bind the leucine zipper domain and disrupt the...
This $687,679 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize the transcriptional regulatory landscape in hepatocellular carcinoma (HCC) and identify novel tumor cell-intrinsic vulnerabilities as potential therapeutic targets.
The research, led by The Trustees of Columbia University in the City of New York, will computationally establish transcriptional master regulators (TMRs) in HCC, confirm their...
This $577,034 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research by the Sloan-Kettering Institute for Cancer Research on the role of cancer cell mechanics and the tumor microenvironment in metastasis and immunosurveillance. The key objectives are to:
Examine how distinct metastatic microenvironments affect cancer cell biomechanics and immune vulnerability in mouse models and human samples.
Determine if...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,107,000 three-year Project Grant to The University of Texas Southwestern Medical Center in Dallas, TX. The grant, effective September 1, 2023, will fund research to characterize the epigenetic and metabolic vulnerabilities in clear cell renal cell carcinoma (ccRCC) with VHL gene deficiencies, and explore the therapeutic potential of these findings. The University of Texas System will...
The University of Chicago was awarded a $230,010 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop innovative methods and tools to investigate the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The research strategy will integrate human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing...